Halfway through its fiscal year, Medtronic is finally filling the vacancy at the helm of its neuromodulation operating unit.

在财政年度的中途，美敦力终于填补了其神经调节运营部门的空缺。

The company has selected Paolo Di Vincenzo to take on the role, effective Oct. 30, it said in an announcement this week.

该公司在本周的一份公告中表示，已选择保罗·迪文森佐（PaoloDiVincenzo）担任该职位，自10月30日起生效。

He’ll replace Nnamdi Njoku, the former president of the segment, who left Medtronic in March to join Zimmer Biomet as president of sports medicine, surgical, upper extremities and restorative therapies, according to Njoku’s LinkedIn page.

据Njoku的LinkedIn页面报道，他将接替该部门前总裁Nnamdi Njoku，后者于3月离开美敦力加入Zimmer Biomet，担任运动医学，外科，上肢和修复疗法的总裁。

Di Vincenzo, meanwhile, is joining Medtronic fresh off a nearly decade-long stint at Smith+Nephew, where he held various global marketing and leadership roles, culminating in a term as a senior VP for the British devicemaker and general manager of its advanced wound management business in the U.S.

与此同时，迪文琴佐（DiVincenzo）加入美敦力（Medtronic fresh），结束了在史密斯+侄子（Smith+Nephew）近十年的工作，在那里他担任了各种全球营销和领导角色，最终成为英国设备制造商（the British devicemaker）的高级副总裁和美国高级伤口管理业务的总经理。

Prior to that, Di Vincenzo worked his way up the corporate ladder in a handful of marketing roles at wound care company Systagenix, BD and Roche Diagnostics.

在此之前，迪文琴佐（DiVincenzo）在伤口护理公司Systagenix、BD和罗氏诊断公司（Roche Diagnostics）担任过一些营销角色，在公司的阶梯上不断攀升。

In his new role, he’ll be overseeing both the day-to-day operations and overall strategy of Medtronic’s neuromodulation business, and he’ll report to Brett Wall, president of the company’s neurosciences portfolio.

在他的新职位上，他将负责美敦力神经调节业务的日常运营和整体战略，并向公司神经科学投资组合总裁布雷特·沃尔（BrettWall）汇报。

“Paolo is a results-driven leader who puts people first,” Wall said in the announcement. “I’m thrilled to have him join this team as Neuromodulation moves into the era of personalized medicine with sensing technology. He will play a key role in advancing our capabilities in these areas while driving business execution in alignment with Medtronic’s focus on a performance-driven culture.”.

沃尔在公告中说：“保罗是一位注重结果的领导者，他把人放在首位。”。“随着神经调节技术进入传感技术个性化医疗时代，我很高兴他能加入这个团队。他将在提升我们在这些领域的能力方面发挥关键作用，同时推动业务执行，与美敦力专注于绩效驱动的文化保持一致。”。

The neuromodulation segment—which is joined by Medtronic’s cranial and spinal technologies and specialty therapies divisions under the neuroscience portfolio umbrella—comprises the company’s spinal cord stimulation systems and other implanted neurostimulators.

神经调节部分由美敦力的颅骨和脊柱技术以及神经科学投资组合下的专业治疗部门组成，包括该公司的脊髓刺激系统和其他植入的神经刺激器。

In its most recent financial report, covering the first quarter of its fiscal year 2024, Medtronic reported growth of 3.7% in the neuromodulation business, contributing to the neuroscience portfolio’s overall increase of around 5%. In total, the neuromodulation unit brought in $420 million around the globe for the quarter..

在涵盖2024财年第一季度的最新财务报告中，美敦力报告神经调节业务增长了3.7%，推动了神经科学投资组合的总体增长约5%。总的来说，神经调节部门本季度在全球范围内带来了4.2亿美元的收入。。

The segment got off to a strong start in the second quarter: Medtronic announced in August that it had received European CE mark clearance for its Inceptiv spinal cord stimulator, which is designed to be a closed-loop system—meaning it’ll automatically adjust the neuromodulation therapy it delivers to adapt to users’ movements and reduce discomfort..

该部门在第二季度取得了良好的开端：美敦力于8月宣布，其Inceptiv脊髓刺激器已获得欧洲CE标志许可，该刺激器设计为闭环系统，这意味着它将自动调整其提供的神经调节疗法，以适应用户的动作并减少不适感。。